Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concizumab prophylaxis in hemophilia A or B without inhibitors
MOH_2019-09-23_007336Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of concizumab in hemophilia A and hemophilia B (HB) (4 arms), sponsored by Novo Nordisk. Started Aug 2019; status: completed.
02
Drugs
concizumab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on MOH_2019-09-23_007336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-09-23_007336.